Aliases & Classifications for Nephrolithiasis

MalaCards integrated aliases for Nephrolithiasis:

Name: Nephrolithiasis 39 12 77 30 56 6 45 15 17 74
Kidney Stones 12 15
Nephrolithiasis, Calcium Oxalate 12
Urolithiasis, Calcium Oxalate 12
Calculus of Kidney and Ureter 12
Stone - Kidney/ureter 12
Kidney Calculi 74

Classifications:



External Ids:

Disease Ontology 12 DOID:585
ICD9CM 36 592
MeSH 45 D053040
ICD10 34 N20 N20.2

Summaries for Nephrolithiasis

MalaCards based summary : Nephrolithiasis, also known as kidney stones, is related to nephrolithiasis, calcium oxalate and dominant hypophosphatemia with nephrolithiasis or osteoporosis, and has symptoms including renal pain An important gene associated with Nephrolithiasis is SLC34A1 (Solute Carrier Family 34 Member 1), and among its related pathways/superpathways are Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds and Parathyroid hormone synthesis, secretion and action. The drugs Mirabegron and Tamsulosin have been mentioned in the context of this disorder. Affiliated tissues include Kidney, kidney and bone, and related phenotypes are homeostasis/metabolism and behavior/neurological

Wikipedia : 77 Kidney stone disease, also known as urolithiasis, is when a solid piece of material (kidney stone)... more...

Related Diseases for Nephrolithiasis

Diseases related to Nephrolithiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 231)
# Related Disease Score Top Affiliating Genes
1 nephrolithiasis, calcium oxalate 34.1 AGXT APRT CASR CLCN5 GRHPR SLC26A1
2 dominant hypophosphatemia with nephrolithiasis or osteoporosis 33.8 SLC34A1 SLC9A3R1
3 hypouricemia, renal, 1 32.7 SLC22A12 SLC2A9
4 hypophosphatemic rickets, x-linked recessive 32.6 CLCN5 SLC34A1 SLC34A3
5 hypercalciuria, absorptive, 2 32.5 CASR CLCN5 CLDN16 SLC34A3
6 acute urate nephropathy 32.1 SLC22A12 ZNF365
7 idiopathic hypercalciuria 31.0 CASR CLCN5 SLC34A3
8 gout 30.8 APRT SLC22A12 SLC2A9
9 osteoporosis 30.7 CASR SLC34A1 SLC9A3R1 SPP1
10 hypophosphatemia 30.7 CLCN5 SLC34A1 SLC34A3
11 nephrocalcinosis 30.7 AGXT ATP6V1B1 CASR CLCN5 CLDN16 GRHPR
12 rickets 30.7 CLCN5 SLC34A1 SLC34A3
13 chronic kidney failure 30.7 AGXT CASR CLDN16 SPP1
14 bartter disease 30.4 CASR CLCN5 SLC12A1
15 hereditary hypophosphatemic rickets 30.2 SLC34A1 SLC34A3
16 hypophosphatemic rickets with hypercalciuria, hereditary 30.2 CLDN16 SLC34A1 SLC34A3
17 xanthinuria 30.1 APRT CLDN16 SLC22A12 SLC2A9
18 pulmonary alveolar microlithiasis 29.8 SLC34A1 SLC34A3
19 nephrolithiasis, x-linked recessive, with renal failure 12.6
20 nephrolithiasis, uric acid 12.6
21 nephrolithiasis/osteoporosis, hypophosphatemic, 1 12.4
22 nephrolithiasis/osteoporosis, hypophosphatemic, 2 12.4
23 dent disease 1 12.2
24 adenine phosphoribosyltransferase deficiency 11.5
25 hyperglycinuria 11.5
26 hyperparathyroidism 2 with jaw tumors 11.5
27 renal tubular acidosis, distal 11.3
28 alkaptonuria 11.2
29 dent disease 2 11.2
30 hypocalcemia, autosomal dominant 1 11.2
31 renal tubular acidosis, distal, autosomal dominant 11.1
32 hypotonia-cystinuria syndrome 11.1
33 renal tubular acidosis, distal, with hemolytic anemia 11.1
34 hypouricemia, renal, 2 11.1
35 urolithiasis, uric acid, autosomal dominant 11.0
36 multiple endocrine neoplasia, type i 11.0
37 hypomagnesemia 3, renal 11.0
38 congenital short bowel syndrome 11.0
39 hypocalcemia, autosomal dominant 2 11.0
40 hypoparathyroidism 11.0
41 osteitis fibrosa 11.0
42 familial isolated hyperparathyroidism 11.0
43 hypocalciuric hypercalcemia, familial, type i 11.0
44 polycystic kidney disease 1 with or without polycystic liver disease 11.0
45 hyperoxaluria, primary, type i 11.0
46 hyperoxaluria, primary, type ii 11.0
47 renal tubular acidosis, distal, with progressive nerve deafness 11.0
48 renal tubular acidosis, distal, autosomal recessive 11.0
49 parathyroid carcinoma 11.0
50 familial primary hypomagnesemia with hypercalciuria and nephrocalcinosis 11.0

Graphical network of the top 20 diseases related to Nephrolithiasis:



Diseases related to Nephrolithiasis

Symptoms & Phenotypes for Nephrolithiasis

UMLS symptoms related to Nephrolithiasis:


renal pain

MGI Mouse Phenotypes related to Nephrolithiasis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.19 AGXT APRT ATP6V1B1 BRCA2 CASR CLCN5
2 behavior/neurological MP:0005386 10.1 APRT ATP6V1B1 BRCA2 CASR SLC12A1 SLC22A12
3 growth/size/body region MP:0005378 10.06 APRT BRCA2 CASR CLCN5 SLC12A1 SLC22A12
4 digestive/alimentary MP:0005381 9.91 BRCA2 CASR SLC22A12 SLC26A1 SLC2A9 SLC34A3
5 renal/urinary system MP:0005367 9.86 AGXT APRT ATP6V1B1 CASR CLCN5 CLDN16
6 immune system MP:0005387 9.85 APRT BRCA2 CASR GRHPR SLC12A1 SLC26A1
7 skeleton MP:0005390 9.36 ATP6V1B1 BRCA2 CASR CLCN5 SLC12A1 SLC34A1

Drugs & Therapeutics for Nephrolithiasis

Drugs for Nephrolithiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 349)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mirabegron Approved Phase 4 223673-61-8 9865528
2
Tamsulosin Approved, Investigational Phase 4,Phase 3,Not Applicable 106133-20-4 129211
3
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Not Applicable 103-90-2 1983
4
Ketorolac Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 66635-83-4, 74103-06-3 3826
5
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
6
Ciprofloxacin Approved, Investigational Phase 4,Not Applicable 85721-33-1 2764
7
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 68-04-2
8
Allopurinol Approved Phase 4,Phase 2,Phase 1 315-30-0 2094
9
tannic acid Approved Phase 4,Not Applicable 1401-55-4
10
Benzocaine Approved, Investigational Phase 4,Not Applicable 94-09-7, 1994-09-7 2337
11
Potassium Citrate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable
12
Scopolamine Approved, Investigational Phase 4,Phase 3 6533-68-2, 51-34-3 5184
13
Atropine Approved, Vet_approved Phase 4 51-55-8, 5908-99-6 174174
14
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
15
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 57-27-2 5288826
16
Belladonna Approved, Experimental Phase 4
17
Loperamide Approved Phase 4 53179-11-6 3955
18
Opium Approved, Illicit Phase 4 8008-60-4
19
Verapamil Approved Phase 4 52-53-9 2520
20
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
21
Selenium Approved, Investigational, Vet_approved Phase 4,Not Applicable 7782-49-2
22
Losartan Approved Phase 4 114798-26-4 3961
23
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 71273 175805
24
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
25
Remifentanil Approved Phase 4 132875-61-7 60815
26
Tramadol Approved, Investigational Phase 4,Not Applicable 27203-92-5 33741
27
Bupivacaine Approved, Investigational Phase 4,Phase 3,Not Applicable 2180-92-9, 38396-39-3 2474
28
Pentazocine Approved, Vet_approved Phase 4 359-83-1 441278
29
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
30
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
31
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
32
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
33
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
34
Ondansetron Approved Phase 4 99614-02-5 4595
35
Ranitidine Approved Phase 4 66357-59-3, 66357-35-5 3001055
36
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Not Applicable 76-42-6 5284603
37
Alendronate Approved Phase 4,Phase 2 66376-36-1, 121268-17-5 2088
38
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
39
leucovorin Approved Phase 4,Phase 1,Not Applicable 58-05-9 6006 143
40
Ibuprofen Approved Phase 4,Not Applicable 15687-27-1 3672
41
Silodosin Approved Phase 4,Phase 3,Phase 2 160970-54-7
42
Trimethoprim Approved, Vet_approved Phase 4,Not Applicable 738-70-5 5578
43
Nitrofurantoin Approved, Vet_approved Phase 4,Not Applicable 67-20-9 5353830
44
Sulfamethoxazole Approved Phase 4,Not Applicable 723-46-6 5329
45
Cephalexin Approved, Investigational, Vet_approved Phase 4,Not Applicable 15686-71-2 27447
46
Tranexamic Acid Approved Phase 4 1197-18-8 5526
47
Ampicillin Approved, Vet_approved Phase 4,Not Applicable 69-53-4 6249
48
Vancomycin Approved Phase 4 1404-90-6 441141 14969
49
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
50
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635

Interventional clinical trials:

(show top 50) (show all 372)
# Name Status NCT ID Phase Drugs
1 Comparison of Safety and Efficiency of 20w 30w Holmium Laser Device in Treatment of 1-2 cm Diameter Kidney Stones With RIRS Unknown status NCT02451319 Phase 4
2 Comparison of Safety and Efficiency of 20w and 30w Holmium Laser Device in Management of 2-3 cm Diameter Kidney Stones With Retrograde Intrarenal Surgery Unknown status NCT02443909 Phase 4
3 Quality of Life in Patients With Double Loop Ureteral Stent (JJ Silicone Hydrogel Study) Unknown status NCT02489656 Phase 4
4 Comparison of RIRS Versus PCNL Methods, According to Postoperative Pain and Analgesic Demand in 2 to 4 cm Renal Stones Unknown status NCT02430168 Phase 4
5 Is There Any Relation Between Pain and Stone Location in Retrograde Intrarenal Surgery? Unknown status NCT02430883 Phase 4
6 Naftopidil 75mg for Improving Clearance of Urinary Stones Unknown status NCT02011737 Phase 4 naftopidil 75mg
7 Ureteral Stent-related Pain and Mirabegron (SPAM) Trial Unknown status NCT02095665 Phase 4 Mirabegron;Tamsulosin;Tylenol #3
8 The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study Unknown status NCT01323608 Phase 4 Vitamin D3;Placebo
9 The Predictors of Successful Oral Dissolution Therapy in Radiolucent Renal Stones; A Prospective Evaluation Completed NCT02373384 Phase 4 Oral alkalinization (Potassium citrate, Allopurinol)
10 Efficacy of Potassium Sodium Hydrogen Citrate Therapy on Renal Stone Recurrence and/or Residual Fragments After Shockwave Lithotripsy and Percutaneous Nephrolithotomy in Calcium Oxalate Urolithiasis Completed NCT01329042 Phase 4 Potassium-sodium citrate
11 The Use of Belladonna and Opium Suppository in the Treatment of Postoperative Stent Pain Completed NCT03332056 Phase 4 Belladonna and Opium
12 Vitamin D Repletion in Stone Formers With Hypercalciuria Completed NCT01295879 Phase 4 Ergocalciferol
13 Intravenous Ketorolac for Postoperative Pain in Percutaneous Nephrolithotomy Completed NCT00765128 Phase 4 Ketorolac;Placebo
14 Study of Tomography of Nephrolithiasis Evaluation Completed NCT01451931 Phase 4
15 Are There Protective Effects of Antioxidants, Calcium Channel Blocker and Angiotensin Receptor Blocker Against Extracorporeal Shockwaves Lithotripsy Induced Renal Injury? Completed NCT01675362 Phase 4 Antioxidant group;Calcium Channel Blockers;Angiotensin receptor blocker group;Placebo
16 Ultrasound-guided Transmuscular Quadratus Lumborum Block for Percutaneous Nephrolithotomy Completed NCT02818140 Phase 4 Ropivacaine;Saline
17 Efficacy Study of Different Analgesic Options in Kidney Stone Pain Management Completed NCT02187614 Phase 4 Diclofenac;Morphine;Paracetamol;Placebos
18 Remifentanil in Extracorporeal Shock Wave Lithotripsy Completed NCT01452880 Phase 4 Remifentanil;Remifentanil
19 Comparison Between Tramadol Hcl and Other Analgesics in the Treatment of Renal Colic Completed NCT00310908 Phase 4 Tramadol Hcl
20 Tamsulosin for Urolithiasis in the Emergency Dept Completed NCT00382265 Phase 4 tamsulosin
21 Segmental Epidural Anesthesia (SEA) V/S General Anesthesia for PCNL Completed NCT02878512 Phase 4
22 Ultrasound Guided Thoracic Paravertebral Block for Percutaneous Nephrolithotomy Operations in Children Completed NCT02291692 Phase 4
23 The Comparison of Low Thoracic Paravertebral Block Versus Peritubal Infiltration Completed NCT02764008 Phase 4 Bupivacaine
24 Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms Completed NCT01381120 Phase 4 Solifenacin succinate treatment;Oxycodone and acetaminophen combination treatment
25 VITamine D Supplementation in RenAL Transplant Recipients - VITALE Completed NCT01431430 Phase 4 Cholecalciferol 100 000 UI;Cholecalciferol 12 000 UI
26 Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy Completed NCT01882400 Phase 4 Bisphosphonate treatment
27 Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients Completed NCT00914459 Phase 4
28 Struvite Stones Antibiotic Study Recruiting NCT02375295 Phase 4 ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin
29 Impact of Tranexamic Acid Use in Percutaneous Nephrolithotomy Recruiting NCT02966236 Phase 4 Tranexamic Acid;Placebos
30 Study of Ketorolac Versus Opioid for Pain After Endoscopy Recruiting NCT03888144 Phase 4 Oxycodone;Ketorolac
31 Antibiotic Prophylaxis Before Shock Wave Lithotripsy Recruiting NCT03692715 Phase 4 Ciprofloxacin;Placebo
32 Alkalinization by Urologists & Nephrologists Recruiting NCT03035812 Phase 4 Alkali
33 A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL]) Active, not recruiting NCT02384200 Phase 4 nitrofurantoin monohydrate/macrocrystalline capsules;ampicillin;gentamicin;vancomycin;ceftriaxone
34 Trial of Tadalafil, Tamsulosin and Combination for Access Sheath Deployment Enrolling by invitation NCT03229889 Phase 4 Cialis 5Mg Tablet;Flomax 0.4Mg Capsule;Placebo
35 Daily Versus Twice Per Day Tamsulosin for Ureteral Stent Symptoms Enrolling by invitation NCT03799120 Phase 4 Tamsulosin BID
36 Opioid Free Management After Ureteroscopy Not yet recruiting NCT03872843 Phase 4 Norco 5milligram-325milligram Tablet;Ibuprofen 400 MILLIGRAM in 1 TABLET ORAL TABLET, FILM COATED
37 Trial of High Dose Vitamin D in Patient's With Crohn's Disease Terminated NCT02208310 Phase 4 Cholecalciferol 10,000 IU;Cholecalciferol 400 IU
38 Silodosin Versus Tamsulosin for Treatment of Ureteral Stones Terminated NCT02369744 Phase 4 Silodosin;Tamsulosin
39 Use of a Ureteral Access Sheath During Ureteroscopy and Its Effect on Stone Free Rate Terminated NCT00199524 Phase 4
40 The Use of Intranasal Ketoralac for Pain Management Terminated NCT01736358 Phase 4 Intranasal Ketoralac;Placebo
41 A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment Terminated NCT03226899 Phase 4 Lesinurad;XOI;Placebo
42 Pre-induction Analgesia: Multimodel Regimen vs Aceteminophen for Post Ureteroscopy Pain Withdrawn NCT03549611 Phase 4 Multimodal Oral Drug Regimen;Acetaminophen
43 Effects of the Use of Adjuvant Drugs After Extracorporeal Shockwave Lithotripsy (ESWL) in Renal Calculus Unknown status NCT01215708 Phase 3 Tamsulosin
44 Extracorporeal Shock Wave Lithotriptor Indicated for Fragmenting Urinary Stones in the Kidney Unknown status NCT00959153 Phase 3
45 Alfuzosin for Medical Expulsion Therapy of Ureteral Stones Unknown status NCT00713739 Phase 3 Alfuzosin;nifedipine;doxazosin;prazosin
46 ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study Unknown status NCT02155803 Phase 2, Phase 3 ACTHAR Gel (adrenocorticotropic hormone)
47 Renalof in the Dissolution of Renal Calculi in Patients With Recurrent Calcic Lithiasis Completed NCT01022060 Phase 3
48 Low Salt Diet in Idiopathic Hypercalciuria Completed NCT01005082 Phase 2, Phase 3
49 Visceral Pain From the Upper Urinary Tract - a Trial on the Effect of Morphine and Oxycodone in Patients Undergoing PCNL Completed NCT00784472 Phase 3 oxycodone;morphine
50 Pharmacological Modulation of the Intrarenal Pressure During Endourological Procedures in the Upper Urinary Tract Completed NCT00428428 Phase 2, Phase 3 Isoproterenol

Search NIH Clinical Center for Nephrolithiasis

Cochrane evidence based reviews: nephrolithiasis

Genetic Tests for Nephrolithiasis

Genetic tests related to Nephrolithiasis:

# Genetic test Affiliating Genes
1 Nephrolithiasis 30

Anatomical Context for Nephrolithiasis

MalaCards organs/tissues related to Nephrolithiasis:

42
Kidney, Bone, Testes, Heart, Prostate, Liver, Colon
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Nephrolithiasis:
# Tissue Anatomical CompartmentCell Relevance
1 Kidney Proximal Tubule Proximal Tubule Cells Affected by disease, potential therapeutic candidate

Publications for Nephrolithiasis

Articles related to Nephrolithiasis:

(show top 50) (show all 2409)
# Title Authors Year
1
Hepatoid adenocarcinoma of the renal pelvis in a 59-year-old male with nephrolithiasis: Case report and review of the literature. ( 30683324 )
2019
2
Normocalcemic Primary Hyperparathyroidism in Adults Without a History of Nephrolithiasis or Fractures: A Prospective Study. ( 30840998 )
2019
3
Predictors of nephrolithiasis, osteoporosis and mortality in primary hyperparathyroidism. ( 30916764 )
2019
4
Kidney Stones and Risk of Osteoporotic Fracture in Chronic Kidney Disease. ( 30760766 )
2019
5
Total serum magnesium in cats with chronic kidney disease with nephrolithiasis. ( 30694098 )
2019
6
Editorial: Controversies in kidney stones and other chronic kidney disease topics. ( 30585853 )
2019
7
Re: Prevalence of Nephrolithiasis in Patients with Chronic Liver Disease: A Case-Control Study. ( 30864921 )
2019
8
Polymorphisms of the VDR gene in patients with nephrolithiasis in a Han Chinese population. ( 29549381 )
2019
9
Calcium-sensing receptor: evidence and hypothesis for its role in nephrolithiasis. ( 30446806 )
2019
10
Heritable traits that contribute to nephrolithiasis. ( 30460525 )
2019
11
Nephrolithiasis secondary to inherited defects in the thick ascending loop of henle and connecting tubules. ( 30460527 )
2019
12
Living kidney donation from people at risk of nephrolithiasis, with a focus on the genetic forms. ( 30470867 )
2019
13
Urinary proteome in inherited nephrolithiasis. ( 30564846 )
2019
14
Activation of liver X receptor suppresses osteopontin expression and ameliorates nephrolithiasis. ( 30623435 )
2019
15
Changing Trends in the Treatment of Nephrolithiasis in the Real World. ( 30628473 )
2019
16
Re: Urinary Proteomics Reveals Association between Pediatric Nephrolithiasis and Cardiovascular Disease. ( 30634333 )
2019
17
Association between Dyslipidemia and Nephrolithiasis Risk in a Chinese Population. ( 30673680 )
2019
18
Inherited proximal tubular disorders and nephrolithiasis. ( 30673801 )
2019
19
De novo nephrolithiasis causing acute renal transplant dysfunction. ( 30690910 )
2019
20
The Impact of the Image Gently Campaign on CT Use for the Evaluation of Pediatric Nephrolithiasis. ( 30694933 )
2019
21
Association of vitamin D receptor gene polymorphism with the risk of nephrolithiasis. ( 30701705 )
2019
22
Association of sirtuin 1 gene polymorphisms with nephrolithiasis in Eastern chinese population. ( 30714469 )
2019
23
Metformin prevents nephrolithiasis formation by inhibiting the expression of OPN and MCP-1 in vitro and in vivo. ( 30720053 )
2019
24
Net Acid Excretion and Urinary Organic Anions in Idiopathic Uric Acid Nephrolithiasis. ( 30745301 )
2019
25
Gene panel sequencing identifies a likely monogenic cause in 7% of 235 Pakistani families with nephrolithiasis. ( 30778725 )
2019
26
Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. ( 30783195 )
2019
27
Incidental Primary Squamous Cell Carcinoma of the Kidney Within a Calyceal Diverticulum Associated With Nephrolithiasis. ( 30784032 )
2019
28
Patient Characteristics Associated with Completion of 24-hour Urine Analyses Among Children and Adolescents with Nephrolithiasis. ( 30796989 )
2019
29
Medical dissolution therapy for the treatment of uric acid nephrolithiasis. ( 30810833 )
2019
30
Large incidental gastrointestinal stromal tumors in a patient presenting with acutely symptomatic nephrolithiasis: A case report. ( 30847013 )
2019
31
The association of nephrolithiasis with prescription opioid use
. ( 30862351 )
2019
32
Low income and non-White race are strongly associated with worse quality of life for nephrolithiasis patients. ( 30865567 )
2019
33
Re: Incomplete Distal Renal Tubular Acidosis and Kidney Stones. ( 30759664 )
2019
34
Liver transplant, toxoplasmosis and kidney stones: connecting the dots. ( 30772835 )
2019
35
Kidney stones and the risk of renal cell carcinoma and upper tract urothelial carcinoma: the Netherlands Cohort Study. ( 30563989 )
2019
36
Gastrin-releasing peptide receptor gene silencing inhibits the development of the epithelial-mesenchymal transition and formation of a calcium oxalate crystal in renal tubular epithelial cells in mice with kidney stones via the PI3K/Akt signaling pathway. ( 30144073 )
2019
37
Insights about urinary hippuric and citric acid as biomarkers of fruit and vegetable intake in patients with kidney stones: The role of age and sex. ( 30471528 )
2019
38
Empiric therapy for kidney stones. ( 30478476 )
2019
39
The Impact of Dust and Confinement on Fragmentation of Kidney Stones by Shockwave Lithotripsy in Tissue Phantoms. ( 30595048 )
2019
40
Educational review: role of the pediatric nephrologists in the work-up and management of kidney stones. ( 30607567 )
2019
41
High power holmium:YAG versus thulium fiber laser treatment of kidney stones in dusting mode: ablation rate and fragment size studies. ( 30648761 )
2019
42
Re: Variation in National Opioid Prescribing Patterns following Surgery for Kidney Stones. ( 30653004 )
2019
43
Re: Geobiology Reveals how Human Kidney Stones Dissolve In Vivo. ( 30653006 )
2019
44
Re: Hyponatremia and the Risk of Kidney Stones: . ( 30653007 )
2019
45
Mineralogical, compositional and isotope characterization of human kidney stones (urolithiasis) in a Sri Lankan population. ( 30671690 )
2019
46
Meeting report of the "Symposium on kidney stones and mineral metabolism: calcium kidney stones in 2017". ( 30680550 )
2019
47
Differentiating kidney stones from phleboliths in unenhanced low-dose computed tomography using radiomics and machine learning. ( 30747299 )
2019
48
Comparison of tubeless percutaneous nephrolithotomy and standard percutaneous nephrolithotomy for kidney stones: A meta-analysis of randomized trials. ( 30782495 )
2019
49
Editorial comment on END-2018-0516-OR.R1. ( 30808186 )
2019
50
Kidney stones and risk of narcotic use. ( 30829133 )
2019

Variations for Nephrolithiasis

ClinVar genetic disease variations for Nephrolithiasis:

6 (show all 39)
# Gene Variation Type Significance SNP ID Assembly Location
1 AGXT NM_000030.2(AGXT): c.481G> A (p.Gly161Ser) single nucleotide variant Pathogenic/Likely pathogenic rs180177227 GRCh37 Chromosome 2, 241810823: 241810823
2 AGXT NM_000030.2(AGXT): c.481G> A (p.Gly161Ser) single nucleotide variant Pathogenic/Likely pathogenic rs180177227 GRCh38 Chromosome 2, 240871406: 240871406
3 SLC9A3R1 NM_004252.4(SLC9A3R1): c.673G> A (p.Glu225Lys) single nucleotide variant Likely benign rs119486097 GRCh37 Chromosome 17, 72759575: 72759575
4 SLC9A3R1 NM_004252.4(SLC9A3R1): c.673G> A (p.Glu225Lys) single nucleotide variant Likely benign rs119486097 GRCh38 Chromosome 17, 74763436: 74763436
5 GRHPR NM_012203.1(GRHPR): c.103delG (p.Asp35Thrfs) deletion Pathogenic rs80356708 GRCh37 Chromosome 9, 37424861: 37424861
6 GRHPR NM_012203.1(GRHPR): c.103delG (p.Asp35Thrfs) deletion Pathogenic rs80356708 GRCh38 Chromosome 9, 37424864: 37424864
7 AGXT NM_000030.2(AGXT): c.121G> A (p.Gly41Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121908523 GRCh37 Chromosome 2, 241808403: 241808403
8 AGXT NM_000030.2(AGXT): c.121G> A (p.Gly41Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121908523 GRCh38 Chromosome 2, 240868986: 240868986
9 AGXT NM_000030.2(AGXT): c.731T> C (p.Ile244Thr) single nucleotide variant Pathogenic rs121908525 GRCh37 Chromosome 2, 241814576: 241814576
10 AGXT NM_000030.2(AGXT): c.731T> C (p.Ile244Thr) single nucleotide variant Pathogenic rs121908525 GRCh38 Chromosome 2, 240875159: 240875159
11 CLDN16 NM_006580.3(CLDN16): c.695T> G (p.Phe232Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104893726 GRCh37 Chromosome 3, 190126205: 190126205
12 CLDN16 NM_006580.3(CLDN16): c.695T> G (p.Phe232Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104893726 GRCh38 Chromosome 3, 190408416: 190408416
13 ATP6V1B1 NM_001692.4(ATP6V1B1): c.242T> C (p.Leu81Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121964880 GRCh37 Chromosome 2, 71185243: 71185243
14 ATP6V1B1 NM_001692.4(ATP6V1B1): c.242T> C (p.Leu81Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121964880 GRCh38 Chromosome 2, 70958113: 70958113
15 BRCA2 NM_000059.3(BRCA2): c.4936_4939delGAAA (p.Glu1646Glnfs) deletion Pathogenic rs80359473 GRCh37 Chromosome 13, 32913428: 32913431
16 BRCA2 NM_000059.3(BRCA2): c.4936_4939delGAAA (p.Glu1646Glnfs) deletion Pathogenic rs80359473 GRCh38 Chromosome 13, 32339291: 32339294
17 SLC34A1 NM_003052.4(SLC34A1): c.644+1G> A single nucleotide variant Pathogenic/Likely pathogenic rs201304511 GRCh37 Chromosome 5, 176814875: 176814875
18 SLC34A1 NM_003052.4(SLC34A1): c.644+1G> A single nucleotide variant Pathogenic/Likely pathogenic rs201304511 GRCh38 Chromosome 5, 177387874: 177387874
19 SLC12A1 NM_000338.2(SLC12A1): c.1163delT (p.Phe388Serfs) deletion Pathogenic/Likely pathogenic rs779588655 GRCh38 Chromosome 15, 48234952: 48234952
20 SLC12A1 NM_000338.2(SLC12A1): c.1163delT (p.Phe388Serfs) deletion Pathogenic/Likely pathogenic rs779588655 GRCh37 Chromosome 15, 48527149: 48527149
21 46;X;t(X;5)(q24;q13)dn Translocation Pathogenic
22 MT-CO3 NC_012920.1: m.9355A> T single nucleotide variant Uncertain significance rs1556423663 GRCh37 Chromosome MT, 9355: 9355
23 MT-CO3 NC_012920.1: m.9355A> T single nucleotide variant Uncertain significance rs1556423663 GRCh38 Chromosome MT, 9355: 9355
24 CLDN19 NM_148960.2(CLDN19): c.535G> A (p.Gly179Ser) single nucleotide variant Likely pathogenic rs145591298 GRCh38 Chromosome 1, 42735969: 42735969
25 CLDN19 NM_148960.2(CLDN19): c.535G> A (p.Gly179Ser) single nucleotide variant Likely pathogenic rs145591298 GRCh37 Chromosome 1, 43201640: 43201640
26 AGXT NM_000030.2(AGXT): c.1079G> C (p.Arg360Pro) single nucleotide variant Likely pathogenic rs180177161 GRCh38 Chromosome 2, 240878721: 240878721
27 AGXT NM_000030.2(AGXT): c.1079G> C (p.Arg360Pro) single nucleotide variant Likely pathogenic rs180177161 GRCh37 Chromosome 2, 241818138: 241818138
28 SLC3A1 NM_000341.3(SLC3A1): c.592delG (p.Ala198Glnfs) deletion Likely pathogenic rs778000327 GRCh38 Chromosome 2, 44280877: 44280877
29 SLC3A1 NM_000341.3(SLC3A1): c.592delG (p.Ala198Glnfs) deletion Likely pathogenic rs778000327 GRCh37 Chromosome 2, 44508016: 44508016
30 SLC34A1 NM_003052.4(SLC34A1): c.1204G> C (p.Gly402Arg) single nucleotide variant Likely pathogenic rs376131751 GRCh38 Chromosome 5, 177396762: 177396762
31 SLC34A1 NM_003052.4(SLC34A1): c.1204G> C (p.Gly402Arg) single nucleotide variant Likely pathogenic rs376131751 GRCh37 Chromosome 5, 176823763: 176823763
32 SLC34A1 NM_003052.4(SLC34A1): c.1724C> T (p.Thr575Ile) single nucleotide variant Likely pathogenic rs201331677 GRCh38 Chromosome 5, 177398090: 177398090
33 SLC34A1 NM_003052.4(SLC34A1): c.1724C> T (p.Thr575Ile) single nucleotide variant Likely pathogenic rs201331677 GRCh37 Chromosome 5, 176825091: 176825091
34 GRHPR NM_012203.1(GRHPR): c.404+5G> A single nucleotide variant Likely pathogenic rs757796926 GRCh37 Chromosome 9, 37426656: 37426656
35 GRHPR NM_012203.1(GRHPR): c.404+5G> A single nucleotide variant Likely pathogenic rs757796926 GRCh38 Chromosome 9, 37426659: 37426659
36 SLC12A1 NM_000338.2(SLC12A1): c.769G> A (p.Gly257Ser) single nucleotide variant Likely pathogenic rs896545456 GRCh38 Chromosome 15, 48229233: 48229233
37 SLC12A1 NM_000338.2(SLC12A1): c.769G> A (p.Gly257Ser) single nucleotide variant Likely pathogenic rs896545456 GRCh37 Chromosome 15, 48521430: 48521430
38 SLC12A1 NM_000338.2(SLC12A1): c.1424G> A (p.Cys475Tyr) single nucleotide variant Likely pathogenic rs1555466999 GRCh38 Chromosome 15, 48244876: 48244876
39 SLC12A1 NM_000338.2(SLC12A1): c.1424G> A (p.Cys475Tyr) single nucleotide variant Likely pathogenic rs1555466999 GRCh37 Chromosome 15, 48537073: 48537073

Expression for Nephrolithiasis

Search GEO for disease gene expression data for Nephrolithiasis.

Pathways for Nephrolithiasis